Korean Circ J.  2024 Jan;54(1):13-27. 10.4070/kcj.2023.0084.

Risk of Atrial Fibrillation and Adverse Outcomes in Patients With Cardiac Implantable Electronic Devices

• Lee SR
• Lee JH
• Choi EK
• Jung EK
• You SJ
• Oh S
• Lip GY

• KMID: 2550600
• DOI: http://doi.org/10.4070/kcj.2023.0084

Abstract

Background and Objectives
Comprehensive epidemiological data are lacking on the incident atrial fibrillation (AF) in patients with cardiac implantable electronic devices (CIEDs). This study aimed to examine the incidence, risk factors, and AF-related adverse outcomes of patients with CIEDs.
Methods
This was an observational cohort study that analyzed patients without prevalent AF who underwent CIED implantation in 2009–2018 using a Korean nationwide claims database. The subjects were divided into three groups by CIED type and indication: pacemaker (n=21,438), implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy (CRT) with heart failure (HF) (n=3,450), and ICD for secondary prevention without HF (n=2,146). The incidence of AF, AF-associated predictors, and adverse outcomes were evaluated.
Results
During follow-up, the incidence of AF was 4.3, 7.3, and 5.1 per 100 person-years in the pacemaker, ICD/CRT with HF, and ICD without HF cohorts, respectively. Across the three cohorts, older age and valvular heart disease were commonly associated with incident AF. Incident AF was consistently associated with an increased risk of ischemic stroke (3.8–11.4-fold), admission for HF (2.6–10.5-fold), hospitalization for any cause (2.4–2.7-fold), all-cause death (4.1–5.0-fold), and composite outcomes (3.4–5.7-fold). Oral anticoagulation rates were suboptimal in patients with incident AF (pacemaker, 51.3%; ICD/CRT with HF, 51.7%; and ICD without HF, 33.8%, respectively).
Conclusions
A substantial proportion of patients implanted CIED developed newly diagnosed AF. Incident AF was associated with a higher risk of adverse events. The importance of awareness, early detection, and appropriate management of AF in patients with CIED should be emphasized.

Keyword

Atrial fibrillation; Pacemaker; Implantable cardioverter defibrillator; Cardiac resynchronization therapy; Risk factor

Figure

• 

  Figure 1 Study enrollment flow.AF = atrial fibrillation; CIED = cardiac implantable electronic device; CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter defibrillator; IR = incidence rate; PY = person-years.

• 

  Figure 2 AF-free survival curves in each cohort.AF = atrial fibrillation; CRT = cardiac resynchronization therapy; F/U = follow-up; HF = heart failure; ICD = implantable cardioverter defibrillator; IR = incidence rate; PY = person-years.

• 

  Figure 3 Factors associated with incident AF in 3 cohorts.(A) Pacemaker cohort. (B) ICD/CRT with HF cohort. (C) ICD without HF cohort.CAD = coronary artery disease; CI = confidence interval; HR = hazard ratio; MI = myocardial infarction; PAD = peripheral artery disease; TIA = transient ischemic attack; SSS = sick sinus syndrome; VHD = valvular heart disease.

• 

  Figure 4 Crude IRs of AF-related adverse outcomes in each cohort.AF = atrial fibrillation; CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter defibrillator; IR = incidence rate; PY = person-years.

• 

  Figure 5 HRs of incident AF for AF-related adverse outcomes.(A) Pacemaker cohort. (B) ICD/CRT with HF cohort. (C) ICD without HF cohort.AF = atrial fibrillation; CI = confidence interval; CRT = cardiac resynchronization therapy; HF = heart failure; HR = hazard ratio; ICD = implantable cardioverter defibrillator.

Reference

1. Greenspon AJ, Patel JD, Lau E, et al. Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures. J Am Coll Cardiol. 2012; 60:1540–1545. PMID: 22999727.

2. Lee JH, Lee SR, Choi EK, et al. Temporal trends of cardiac implantable electronic device implantations: a nationwide population-based study. Korean Circ J. 2019; 49:841–852. PMID: 31074230.

3. Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study. Chest. 2018; 153:453–466. PMID: 29017957.

4. van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol. 2011; 57:556–562. PMID: 21272746.

5. Santini M, Gasparini M, Landolina M, et al. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol. 2011; 57:167–172. PMID: 21211688.

6. Cheol Seong S, Kim YY, Khang YH, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017; 46:799–800. PMID: 27794523.

7. Lee HJ, Choi EK, Han KD, et al. Bodyweight fluctuation is associated with increased risk of incident atrial fibrillation. Heart Rhythm. 2020; 17:365–371. PMID: 31585180.

8. Lee SR, Choi EK, Kwon S, et al. Oral anticoagulation in Asian patients with atrial fibrillation and a history of intracranial hemorrhage. Stroke. 2020; 51:416–423. PMID: 31813363.

9. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28:3083–3107. PMID: 19757444.

10. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009; 2:474–480. PMID: 19843914.

11. Kim M, Kim TH, Yu HT, et al. Prevalence and predictors of clinically relevant atrial high-rate episodes in patients with cardiac implantable electronic devices. Korean Circ J. 2021; 51:235–247. PMID: 33655723.

12. Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA₂DS₂-VASc score. Circulation. 2019; 140:1639–1646. PMID: 31564126.

13. Al-Gibbawi M, Ayinde HO, Bhatia NK, et al. Relationship between device-detected burden and duration of atrial fibrillation and risk of ischemic stroke. Heart Rhythm. 2021; 18:338–346. PMID: 33250442.

14. Belkin MN, Soria CE, Waldo AL, et al. Incidence and clinical significance of new-onset device-detected atrial tachyarrhythmia: a meta-analysis. Circ Arrhythm Electrophysiol. 2018; 11:e005393. PMID: 29540371.

15. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012; 366:120–129. PMID: 22236222.

16. Pedersen KB, Madsen C, Sandgaard NC, Diederichsen AC, Bak S, Brandes A. Subclinical atrial fibrillation in patients with recent transient ischemic attack. J Cardiovasc Electrophysiol. 2018; 29:707–714. PMID: 29478291.

17. Chent XL, Ren XJ, Liang Z, Han ZH, Zhang T, Luo Z. Analyses of risk factors and prognosis for new-onset atrial fibrillation in elderly patients after dual-chamber pacemaker implantation. J Geriatr Cardiol. 2018; 15:628–633. PMID: 30416511.

18. Wachter R, Freedman B. Subclinical atrial fibrillation and the risk of recurrent ischemic stroke. Thromb Haemost. 2021; 121:697–699. PMID: 34020463.

19. Turagam MK, Garg J, Whang W, et al. Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials. Ann Intern Med. 2019; 170:41–50. PMID: 30583296.

20. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008; 5:704–709. PMID: 18452873.

21. Hayashi H, Sumiyoshi M, Nakazato Y, Daida H. Brugada syndrome and sinus node dysfunction. J Arrhythm. 2018; 34:216–221. PMID: 29951135.

22. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42:373–498. PMID: 32860505.

23. Lee SS, Ae Kong K, Kim D, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J. 2017; 38:2599–2607. PMID: 28662568.

24. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med. 2000; 342:1385–1391. PMID: 10805823.

25. Pastore G, Zanon F, Baracca E, et al. The risk of atrial fibrillation during right ventricular pacing. Europace. 2016; 18:353–358. PMID: 26443444.